Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France

Authors Schernberg A, Sagaon-Teyssier L, Schwarzinger M

Received 14 December 2018

Accepted for publication 28 March 2019

Published 22 July 2019 Volume 2019:11 Pages 441—451

DOI https://doi.org/10.2147/CEOR.S198312

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Dean Smith


Antoine Schernberg,1 Luis Sagaon-Teyssier,2,3 Michaël Schwarzinger,3,4 On behalf of the EPICORL Study Group

1Department of Radiation Oncology, Hôpital Tenon, AP-HP, Paris, France; 2Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France; 3Translational Health Economics Network (THEN), Paris, France; 4Infection Antimicrobials Modeling & Evolution (IAME), UMR 1137, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Objectives: To evaluate the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France.
Methods: All 53,255 incident adult patients discharged with a first diagnosis of HNSCC in 2010–2012 were identified from the 2008–2013 French National Hospital Discharge (PMSI) database. We conducted a retrospective longitudinal analysis of prognosis and direct costs attributable to HNSCC.
Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in 2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients (41,909 vs 32,221 euros over 3 years, respectively; p<0.001). HNSCC stage at initial treatment was the major driver of mean (SD) direct costs over 3 years (p<0.001): 19,819 (23,150) euros in 31% patients diagnosed at early stage; 46,791 (34,841) euros in 60% patients diagnosed at locally advanced stage; and 43,377 (33,953) euros in 9% patients diagnosed with distant metastasis. About half patients died over 3 years at a median (IQR) age of 63 (56–75) years resulting in 10.9 years-of-life lost on average per incident patient.
Conclusion: The present study suggests that the clinical and economic burden of HNSCC is substantial in France.

Keywords: head and neck squamous cell carcinoma, prognosis, costs, burden of disease, National Hospital discharge database

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]